Research programme: antifungals - Cytomics SystemsAlternative Names: CC 0105; CC 0262; CSY 001; CYD 1274
Latest Information Update: 07 Jan 2011
At a glance
- Originator Cytomics Systems
- Mechanism of Action Ubiquitin-protein ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 07 Jan 2011 Discontinued - Preclinical for Mycoses in France (unspecified route)
- 11 Jun 2005 Preclinical trials in Mycoses in France (unspecified route)